Inclusion Criteria:

- Documented EGFR mutation

- Documented c-MET amplification

- Prior clinical benefit on EGFR inhibitors and then subsequent progression

-≥ 18 year old

- Life expectancy of ≥ 3 months

- ECOG performance status ≤ 2

Exclusion Criteria:

- Unable to swallow tables once or twice daily

- Previous treatment with c-MET inhibitor

- Any unresolved toxicity form previous anticancer therapy greater than grade 1

- History of cystic fibrosis

- History of acute or chronic pancreatitis

- Unable to undergo MRI or CT sans

- Known history of HIV

- Undergone a bone marrow or solid organ transplant

- Clinically significant wound or lung tumor lesions with increased likelihood of
bleeding

- Pregnant or nursing

Other protocol-defined inclusion/exclusion criteria may apply